Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
February 12, 2007
- Trial Fails to Show Non-Inferiority of Iressa to Docetaxel
February 12, 2007
- 7 Drugs/5 APIs Recommended for Approval
February 12, 2007
- Sysmex Launches New Automated Hematology Analyzer in Europe
February 12, 2007
- Dialogue to Be Held Once or Twice a Year: EAD Director
February 12, 2007
- ON THE MOVE
February 12, 2007
- 1st Gov't-Private Sector Dialogue Held
February 12, 2007
- BUSINESS NEWS IN BRIEF
February 12, 2007
- NEW PRODUCTS
February 12, 2007
- AstraZeneca to Cut 3,000 Jobs Worldwide
February 12, 2007
- Tanabe Seiyaku, Mitsubishi Pharma Corporation to Merge Oct. 1
February 12, 2007
- Tohoku Univ. Researchers Develop New Endoscopic Laser Treatment System
February 12, 2007
- Olympus Applies for Swallowable Imaging Capsule
February 12, 2007
- PREMINENT Opens Door to Combination Drugs
February 12, 2007
- Olympus Launches World's First AFT Videoscopes
February 12, 2007
- Toyama Starts PI Trial for Anti-Flu Drug T-705
February 5, 2007
- NEW PRODUCTS
February 5, 2007
- Fewer than Half of All Women Aware that Pill Can Boost Fertility
February 5, 2007
- Reexamination Period to Be Extended to Eight Years: PFSB
February 5, 2007
- Ajinomoto Licenses Novel Diabetes Treatment to BI
February 5, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…